---

🧪 LITHIUM — A Complete Clinical Reference

---

1. HISTORY

• Mid-1800s — Lithium urate was used to treat gout (incorrectly believed to dissolve uric acid crystals)
• Early 1900s — Lithium bromide used as a sedative/hypnotic; lithium iodide tried for syphilis
• 1940s — Lithium chloride marketed as a salt substitute for cardiac/hypertensive patients → multiple deaths reported → withdrawn from US market due to unmonitored toxicity
• 1949 — John Cade (Australian psychiatrist) discovered that lithium carbonate calmed guinea pigs and subsequently treated manic patients — landmark discovery. Published in Medical Journal of Australia.
• 1950s–1960s — Mogens Schou (Denmark) ran the first controlled trials confirming lithium's efficacy in bipolar disorder
• 1970 — FDA approved lithium for treatment of acute mania in the United States
• Later approvals — Extended to maintenance/prophylaxis of bipolar disorder; now also recognized for its unique anti-suicide properties

"Lithium is the only drug treatment for bipolar disorder associated with a reduced risk of suicide." — Rosen's Emergency Medicine

---

2. CHEMISTRY

• Lightest of the alkali metals (Group Ia); atomic number 3
• Monovalent cation (Li⁺) — shares chemical similarities with Na⁺ and K⁺
• Unlike Na⁺/K⁺: Li⁺ develops only a small gradient across biological membranes and is not a substrate for the Na⁺/K⁺-ATPase pump
• Cannot maintain membrane resting potential (can support a single action potential but not repetitive firing)
• Detectable in brain tissue by ⁷Li MRS (magnetic resonance spectroscopy)
• No known physiological role in humans at trace concentrations

---

3. FORMULATIONS & ROUTES

• Route: Oral only (no IV or IM formulation for psychiatric use)
• Note: Some preparations contain lactose — may cause diarrhea in lactose-intolerant patients

---

4. PHARMACOKINETICS

Absorption

• Rapidly and completely absorbed from the GI tract
• Immediate-release: peak serum level 1–2 hours post-dose
• Sustained-release: peak at 4–5 hours post-dose
• Absorption may be delayed in overdose or with concretion formation in the gut
• Food does not significantly alter absorption; can reduce GI side effects

Distribution

• Not protein-bound (0%)
• Volume of distribution: ~0.6–0.9 L/kg (approximates total body water)
• Distributed throughout total body water; enters all body compartments
• Crosses the blood-brain barrier (with some delay — ⁷Li MRS studies confirm rapid BBB crossing); brain:plasma ratio ~0.5–1.0
• Crosses the placenta freely; present in breast milk (~50% of maternal serum level)
• Does NOT bind to plasma proteins — unlike most psychotropics

Metabolism

• Not metabolized at all (no hepatic first-pass effect, no cytochrome P450 involvement)
• Excreted unchanged in urine

Elimination

• Renal excretion exclusively
• Filtered freely at the glomerulus; ~80% reabsorbed in the proximal tubule (competing with Na⁺) — this is the critical pharmacokinetic vulnerability
• Half-life: 18–24 hours in healthy adults; up to 36 hours in elderly patients (age 70s); shorter in children/adolescents
• Steady state: Achieved in approximately 5 days (4–5 half-lives)
• Serum levels must be drawn 10–12 hours after the last dose (standardized trough)

Steady-State Serum Levels & Targets

Outpatient levels should never exceed 1.2 mEq/L, as levels above this increase risk of long-term renal insufficiency by 74% (Goodman & Gilman)

Special Populations — Pharmacokinetics

• Elderly: Reduced total body water + reduced creatinine clearance → reduced safety margin; target lower levels (0.6–0.8 mEq/L)
• Children/adolescents: Clearance correlates with total body weight (especially fat-free mass); lower half-life; may need more frequent dosing
• Pregnancy: Total body water increases → lithium volume of distribution increases → dose must be increased during pregnancy; immediately postpartum, requirements drop abruptly → risk of toxicity at delivery
• Renal impairment: Dramatically reduced clearance; if eGFR <50 mL/min, strongly consider alternatives

---

5. MECHANISM OF ACTION (PHARMACODYNAMICS)

A. Inositol Depletion Hypothesis (Primary)

• Li⁺ uncompetitively inhibits inositol monophosphatase (IMPase) and inositol polyphosphate 1-phosphatase
• This depletes free inositol, reducing resynthesis of phosphatidylinositol (PI)
• Reduces availability of the PI → PLC → IP₃ → DAG → PKC signaling cascade
• Effect is use-dependent (most pronounced in hyperactive neurons) — elegant selectivity for overactive circuits
• Valproate shares this mechanism (via different enzyme: myo-inositol-1-phosphate synthase inhibition)

B. GSK-3β Inhibition (Major — Direct)

• Li⁺ directly inhibits glycogen synthase kinase-3β (GSK-3β)
• GSK-3β regulates:
  • β-catenin signaling (Wnt pathway) → neuroprotection
  • Circadian rhythm (GSK-3β phosphorylates clock proteins)
  • Apoptosis, synaptic plasticity, neurogenesis
• Inhibiting GSK-3β → increased hippocampal β-catenin → mood stabilization
• This may underlie lithium's neuroprotective and possible anti-Alzheimer effects

C. PKC Inhibition

• Long-term treatment decreases protein kinase C (PKC) isoforms α and β
• Reduces cytoplasm-to-membrane translocation of PKC
• Reduces PKC-stimulated serotonin release in cortex/hippocampus
• PKC hyperactivation disrupts prefrontal cortical regulation → mania; Li⁺ normalizes this
• Reduces expression of MARCKS protein (myristoylated alanine-rich C kinase substrate) — implicated in synaptic/neuronal plasticity

D. Serotonin Enhancement

• Facilitates presynaptic 5-HT release
• Desensitizes 5-HT1B autoreceptors (terminal autoreceptors) → enhanced serotonergic neurotransmission
• This underlies lithium augmentation of antidepressants

E. Monoamine Modulation

• Modest enhancement of norepinephrine reuptake and altered receptor sensitivity
• Reduces catecholamine-related hyperactivity (relevant to antimanic effect)
• Limited direct effect on adenylyl cyclase or monoamine receptor binding per se

F. Ion Channel / Membrane Effects

• Li⁺ cannot substitute for Na⁺ at the Na⁺/K⁺-ATPase → cannot maintain membrane resting potential
• Substitutes for Na⁺ in single action potentials but not repetitive firing → may dampen pathological neuronal excitability

G. Neuroprotection & Neuroplasticity

• Upregulates BDNF (brain-derived neurotrophic factor) and bcl-2 (anti-apoptotic protein)
• Increases gray matter volume (demonstrated on MRI)
• May be neuroprotective against tau pathology (via GSK-3β → tau hyperphosphorylation inhibition)

---

6. INDICATIONS

FDA-Approved

1. Acute manic episodes of Bipolar I Disorder
2. Maintenance therapy of Bipolar I Disorder (prophylaxis of mania and depression)

Evidence-Based Off-Label (Psychiatric)

Non-Psychiatric Uses (Historical/Reported)

• Neurological: Cluster headaches (chronic), migraine (cyclic), Huntington disease, L-dopa-induced dyskinesias, Tourette disorder, periodic paralysis
• Hematological: Drug-induced neutropenia (carbamazepine, antipsychotic, zidovudine-related), aplastic anemia, cancer chemotherapy/radiotherapy-induced leukopenia, Felty syndrome
• Endocrine: Thyroid cancer (adjunct to radioiodine), SIADH, thyrotoxicosis
• Dermatological: Genital herpes (topical/oral — controlled studies support), seborrhoeic dermatitis
• GI: Cyclic vomiting

---

7. DOSAGE & DOSING GUIDELINES

Initial Medical Workup (Before Starting)

• Serum creatinine / eGFR (24-hour urine if any renal concern)
• Electrolytes (Na⁺ crucial — hyponatremia increases lithium levels)
• TSH, free T4, T3
• CBC
• ECG (especially if cardiac history; screen for Brugada syndrome)
• Pregnancy test in women of childbearing age
• Weight, BMI baseline

Starting Dose

• Adults: 300 mg immediate-release TID (900 mg/day) → adjust based on serum levels
• Elderly / Renal impairment: 300 mg OD or BID → titrate slowly
• After 5 days → check serum level (10–12 hrs post-dose) → adjust

Maintenance Dose

• Controlled-release can be given once daily (reduces polyuria, preferred for renal protection)
• Serum monitoring: every 5 days when adjusting → then monthly × 3–6 months → then every 3–6 months once stable

Acute Mania Loading (Goodman & Gilman)

• Extended-release preparation: 3 × 10 mg/kg at 4 PM, 6 PM, 8 PM → continue next day once-nightly dosing
• Target serum level: 1.0–1.5 mEq/L for acute mania

Dose Calculation Rule

New dose = (Current dose × Desired level) ÷ Current serum level

---

8. SIDE EFFECTS

A. Common / Early (Therapeutic Doses)

B. Long-Term / Serious

C. Rare

• Peripheral neuropathy
• Benign intracranial hypertension (pseudotumor cerebri)
• Myasthenia gravis-like syndrome
• Exophthalmos
• Lowered seizure threshold
• Mild parkinsonism
• Nephrotic syndrome

D. Cognitive / Psychiatric (Benign but Impairs Compliance)

• Impaired creativity, subjective cognitive blunting
• Emotional blunting / "flat" mood (at therapeutic levels — not toxicity)
• Fatigue (often improves with time)

---

9. TOXICITY

Classification of Lithium Toxicity

Toxicity Levels

Early Signs of Toxicity

• Coarse tremor (vs. fine tremor at therapeutic doses)
• Dysarthria
• Ataxia, gait disturbance
• GI: nausea, vomiting, diarrhea
• Renal dysfunction

Late/Severe Toxicity Signs

• Impaired consciousness / delirium
• Muscular fasciculations, myoclonus, clonus
• Seizures
• Cardiac dysrhythmias (T-wave inversions most common ECG finding)
• Coma and death

SILENT syndrome (Syndrome of Irreversible Lithium-Effectuated Neurotoxicity)

• Persistent neurological damage even after lithium discontinuation and normalization of levels
• Cerebellar dysfunction, dementia — rare but severe sequela of severe toxicity

Chronic Lithium Nephropathy

• Long-term (>10 years) use can cause:
  • Interstitial fibrosis, tubular atrophy
  • Microcyst formation (MRI detectable — avoids renal biopsy)
  • Slowly progressive ↓ GFR
  • Rare end-stage renal failure

Management of Toxicity

1. Discontinue lithium immediately
2. IV crystalloid hydration — essential; enhances renal lithium excretion
3. Serial serum lithium levels every 2–4 hours to track peak and trajectory
4. No role for activated charcoal (Li⁺ is not adsorbed to charcoal)
5. No role for whole-bowel irrigation (routine)
6. Diuretics are CONTRAINDICATED (thiazides and loop diuretics reduce lithium clearance)
7. Hemodialysis — indicated when:
   • Acute level >5.0 mEq/L, OR
   • Severe neurologic toxicity (tremor, clonus, AMS, seizures) regardless of serum level
   • Note: Lithium redistributes from tissues back into blood after dialysis → repeat dialysis may be needed

---

10. DRUG INTERACTIONS

Drugs That INCREASE Lithium Levels (→ Toxicity Risk)

Drugs That DECREASE Lithium Levels (→ Sub-therapeutic Risk)

Pharmacodynamic Interactions

AT1 vs ACEi Nuance

• ACE inhibitors: Increase lithium levels → toxicity risk
• AT1 blockers (ARBs): Losartan and irbesartan do not affect lithium levels — safer choice if RAS blockade needed

---

11. CONTRAINDICATIONS

Absolute

• Brugada syndrome (known or suspected) — lithium may unmask/precipitate lethal arrhythmia
• Severe renal failure (unable to excrete Li⁺ safely)
• Severe cardiac disease with arrhythmias or conduction defects
• Pregnancy — First Trimester (relative/near-absolute): teratogenicity risk — Ebstein's anomaly (tricuspid valve malformation) with first-trimester exposure (absolute risk ~0.1%; relative risk elevated above background)
• Breastfeeding (relative): lithium ~50% maternal serum level in breast milk; risk of neonatal toxicity

Relative Contraindications / High Caution

• Any renal impairment (eGFR <60 mL/min — use lower doses + more frequent monitoring; avoid if eGFR <30 mL/min)
• Sodium-depleted states — low-Na⁺ diet, vomiting, diarrhea, dehydration, diuretics → Li⁺ reabsorbed in Na⁺'s place
• Hypothyroidism — lithium worsens; needs monitoring/replacement before starting
• Psoriasis — lithium exacerbates psoriasis
• Parkinson disease — may worsen symptoms
• Epilepsy — lithium lowers seizure threshold
• Myasthenia gravis — risk of exacerbation
• Concurrent NSAID use — avoid if possible
• Elderly — reduced clearance, increased drug interactions, narrower safety margin

---

12. PRECAUTIONS & MONITORING

Baseline Tests

• Serum creatinine, eGFR
• Serum electrolytes (especially Na⁺)
• TSH, T4
• CBC
• ECG (screen for Brugada)
• Pregnancy test (women of childbearing age)
• Weight/BMI
• Blood pressure

Ongoing Monitoring Schedule

Patient Education — Must Include

• Maintain adequate salt and fluid intake (no low-Na diets; ensure hydration)
• Report diarrhea, vomiting, fever, or decreased fluid intake immediately (→ risk of toxicity)
• Avoid NSAIDs (use acetaminophen/paracetamol instead)
• Report all new prescriptions to treating physician
• Do not stop lithium suddenly
• Carry a lithium alert card

---

13. DISCONTINUATION

• Never stop abruptly — abrupt discontinuation associated with:
  • High risk of relapse (28× more likely post-discontinuation)
  • Possible loss of subsequent lithium response (re-treatment may be ineffective)
  • "Discontinuation syndrome" / rebound mania
• Taper gradually over weeks to months
• Before ECT: Discontinue 2 days prior (prevents delirium)
• If lithium fails after years of successful use → add carbamazepine or valproate before discontinuing lithium

---

14. GUIDELINES — LITHIUM RECOMMENDATIONS

APA (American Psychiatric Association) — Practice Guideline for Bipolar Disorder

• First-line agent for acute mania in Bipolar I Disorder
• First-line for long-term maintenance (Level A evidence)
• Recommended for bipolar depression (in combination with antidepressants if needed)
• Specifically recommended when suicide risk is high — unique anti-suicide efficacy
• Monitoring of renal and thyroid function required

NICE (UK National Institute for Health and Care Excellence) — CG185 Bipolar Disorder (2014, updated)

• First-line treatment for long-term management of bipolar disorder
• Preferred maintenance agent over valproate in women of childbearing age when reproductive risk is discussed
• Lithium is preferred for prophylaxis when other agents have failed
• Monitoring requirements explicitly specified (renal, thyroid, calcium at baseline and every 6 months)
• NICE recommends patient lithium alert card and lithium level monitoring card

Maudsley Prescribing Guidelines (15th Edition)

• Lithium is the gold-standard prophylactic for bipolar disorder
• Target range for maintenance: 0.6–0.8 mmol/L (conservative); acute mania: 0.8–1.0 mmol/L
• Drug interaction table (Table 2.2) is essential clinical reference
• Specific guidance on lithium + clozapine combination for neutropenia management
• Notes no clinically significant PK difference between UK brands (Priadel vs. Camcolit)

BAP (British Association for Psychopharmacology) Guidelines

• Lithium rated as evidence level A for:
  • Acute mania
  • Prevention of mania and depression
  • Anti-suicide effect
• Recommended as preferred agent in uncomplicated bipolar disorder when renal function allows

CANMAT (Canadian Network for Mood and Anxiety Treatments)

• Level 1 evidence for lithium in:
  • Acute mania (monotherapy or combination)
  • Bipolar maintenance
  • Bipolar II maintenance
• Also first-line for adjunctive use in treatment-resistant unipolar depression

WFSBP (World Federation of Societies of Biological Psychiatry)

• Grade A recommendation for acute mania
• Grade A for long-term prophylaxis
• Anti-suicidal effect highlighted as unique and clinically important

Recent Evidence (PubMed, 2023–2025)

• PMID 40441661 (2025 meta-analysis, J Affect Disord): Lithium significantly reduces suicidal ideation, behavior, and completed suicide — updated systematic review confirms unique efficacy
• PMID 39191865 (2025 network meta-analysis, Mol Psychiatry): Among all pharmacotherapies for acute mania, lithium maintains strong comparative efficacy vs. newer agents
• PMID 39128561 (2025 systematic review, JAACAP): In children and adolescents with acute mania, lithium/antiepileptics show comparable efficacy to antipsychotics

---

15. SUMMARY CARD

---

• Katzung's Basic and Clinical Pharmacology, 16e, Ch. 29
• Goodman & Gilman's Pharmacological Basis of Therapeutics, Ch. 19
• Kaplan & Sadock's Synopsis of Psychiatry, Ch. 21 (Section 21.7)
• The Maudsley Prescribing Guidelines in Psychiatry, 15e, Section 2
• Rosen's Emergency Medicine, Ch. 149 (Lithium Toxicity)
• Tintinalli's Emergency Medicine, Ch. 181
• PubMed: PMID 40441661, 39191865, 39128561